J. Brent Muhlestein, M.D.
J. Brent Muhlestein, M.D. |
|
Current Titles:
Director of Cardiology Research, Intermountain Healthcare and Intermountain Medical Center
Director of the Intermountain Medical Center/University of Utah Interventional Cardiology Training Program
Professor of Medicine, University of Utah
Honorary Professor of Medicine at Xian Medical University, People's Republic of China
Clinical Interests:
Interventional cardiology
Research Interests:
Interventional cardiology
Novel risk factors of atherosclerosis (infectious and inflammatory etiologies)
Cardiovascular clinical outcomes
Society Memberships:
American Heart Association
American Medical Association
Utah Medical Association
American College of Cardiology (Fellow)
American College of Physicians (Fellow)
American Association of Interventional Cardiologists
Pertinent Publications:
1. Lim CS, Chapman GD, Gammon RS, Muhlestein JB , Bauman RB, Stack RS, Swain JL. Direct in vivo Gene transfer into the coronary and peripheral vasculature of the intact dog. Circulation 1991; 83:2007-2001.
2. Muhlestein JB , Quigley PJ, Bauman RB, Sketch MH, Tcheng JE, Davidson CJ, Peter RH, Behar VS, Krukoff MW, Kong Y, Phillips HR. A prospective analysis of possible myocardial damage or hemolysis occurring as a result of prolonged autoperfusion angioplasty in humans. JACC 1992; 20:594-598.
3. Muhlestein JB, Phillips HR, Quigley PJ, Bauman RP, Gammon RS, Chapman GD, Mikat EM, Palmos EP, Overmann AB, Stack RS. Early and late outcome following deployment of a new flexible tantalum intracoronary stent in dogs. Am Heart J 1992; 124(4):1058-1067.
4. Sketch MH, Quigley PJ, Perez JA, Davidson CJ, Muhlestein JB, Herndon JE, Glower DD, Phillips HR, Califf RM, Stack RS. Angiographic follow-up after internal mammary artery graft angioplasty. JACC 1992; 70(3):401-403.
5. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333:764-769.
6. Muhlestein JB , Hammond EH, Carlquist JF, Radicke E, Thompson MJ, Karagounis LA, Woods ML, Anderson JL. Increased Incidence of Chlamydia Species within the Coronary Arteries of Patients with Symptomatic Artherosclerotic versus Other Forms of Cardiovascular Disease. JACC 1996; 27:1555-1561.
7. Muhlestein JB. Cost-effective Utilization of Abciximab During Coronary Angioplasty in the Setting of Unstable Angina : A Case Study. J Invasive Card 1996; 8(suppl B):48B-50B.
8. Gomez MA, Anderson JL, Karagounis LA, Muhlestein JB, Mooers FB, for the ROMIO Group. An Emergency Department Based Protocol for Rapid Rule-out of Myocardial Ischemia Reduces Hospital Time and Expense: Results of a Randomized Study (ROMIO). JACC 1996; 28:25-33.
9. Gurbel PA, Navetta FI, Bates ER, Muller DW, Tenaglia AN, Miller MJ, Muhlestein JB , Hermiller JB, Berdan LG, Leimberger JD, Bovill EG, Christenson RH, Ohman EM. Lesion-directed Administration of Alteplase with Intracoronary Heparin in Patients with Unstable Angina and Coronary Thrombus Undergoing Angioplasty. Catheterization and Cardiovascular Diagnosis 1996; 37:382-391.
10. Anderson JL, Karagounis LA, Muhlestein JB. Explaining Discrepant Mortality Results between Primary Percutaneous Transluminal Coronary Angioplasty and Thrombolysis for Acute Myocardial Infarction. JACC 1996; 78(8):934-939.
11. Muhlestein JB , Zhang Q, Parker DJ, Horn SD, Parker DL, Anderson JL. A comparison of the accuracy and reproducibility of digital three-dimensional coronary artery reconstructions using edge detection of videodensitometry. Computers & Biomedical Research 1997; 30(6):415-26.
12. Muhlestein JB . Antiplatelet agents in clinical practice: an economic perspective. Fibrinolysis and Proteolysis 1997.
13. Muhlestein JB , Wardeh A, Karagounis LA, Trehan S, Anderson JL. Rescue Utilization of Abciximab for the Dissolution of Coronary Thrombus Developing as a Complication Coronary Angioplasty. JACC 1997; 30(7):1729-1734.
14. Huang S, Chapman BE, Muhlestein JB, Blatter DD, Parker DL. Computer simulation of convection and diffusion effects on velocity estimations from x-ray contrast density time curves. Lecture Notes in Computer Science 1997; 1230:453-458.
15. Huang S, Decker RJ, Goodrich KC, Parker DJ, Muhlestein JB, Blatter DD, Parker DL. Velocity measurement based on bolus tracking with the aid of three-dimensional reconstruction from digital subtraction angiography. Am Assoc Phys Med 1997; 4(5):677-686.
16. Anderson JL, King GJ, Thompson MJ, Todd M, Bair TL, Muhlestein JB, Carlquist JF. A mutation in the methylenetetrahydofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. JACC 1997; 30(5):1206-1211.
17. The IMPACT-II Investigators . Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349(9063):1422-1428.
18. The EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 335:1689-1696.
19. Coumadin Aspirin Reinfarction Study (CARS) Investigators . Randomized double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350:389-396.
20. Stone GW, de Marchena E, Dageforde D, Foschi A, Muhlestein JB, McIvor M, Rizik D, Vanderlaan R. A prospective, randomized, multicenter comparison of laser angioplasty versus balloon angioplasty – The LAVA Trial. JACC 1997; 30(7):1714-1721.
21. Muhlestein JB , Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF. Infection with chlamydia pneumoniae accelerates the development of artherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97:633-636.
22. Bauriedel G, Hutter R, Luderitz B, Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF. Azithromycin, Chlamydia pneumoniae, and Intimal Thickening. Circulation 1998; 98(21):2357.
23. Anderson JL, Carlquist JF, King GJ, Muhlestein JB, Horne BD, Elmer SP. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. JACC 1998; 32(1):35-41.
24. The EPISTENT Investigators . Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352:87-92.
25. Anderson JL, Carlquist JF, King GJ, Morrison L, Thompsen MJ, Ludwig E, Muhlestein JB , Bair TL, Ward RH. Angiotensin-converting enzyme genotypes and risk for myocardial infarction in women. JACC 1998; 31:790-796.
26. The PUSUIT Trail Investigators . Inhibition on platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Eng J Med 1998; 339(7):436-443.
27. Taylor GS, Muhlestein JB, Wagner GS, Bair TL, Li P, Anderson JL. Implementation of a Computerized Cardiovascular Information System in Private Practice. Am Heart J 1998; 136(5):792-803.
28. Anderson JL, Muhlestein JB, Carlquist JF, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne BD, Lim T. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for chlamydia pneumoniae infection: The azithromycin in coronary artery disease: Elimination of myocardial infection with chlamydia (ACADEMIC) study. Circulation 1999; 99(12):1540-1547.
29. Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, Carlquist JF. Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. JACC 1999; 33(3):727-733.
30. Anonymous. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refactory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomized trial. Lancet 1999; 353(9151):429-38.
31. Anman EM, Giuglano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AAJ, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E, for the TIMI 14 Investigators. Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999; 99:2720-2732.
32. Muhlestein JB . Animal models of chlamydia and artherosclerosis. Am Heart J 1999; 138(5): S514-S515.
33. Gilchrist IC, Gardner LH, Muhlestein JB, Arnold AM, Lincoff AM, Califf RM, Tcheng JE, Topol EJ. Effect of institutional volume and academic status on outcomes of coronary interventions: The IMPACT-II experience. Am Heart J 1999; 138(5):976-982.
34. Anderson JL, Muhlestein JB, Habashi J, Carlquist JF, Bair T, Elmer SB, Davis BP. Lack of association of a common polymorphism of the plasminogen activator inhibitor – 1 gene with coronary artery disease and myocardial infarction. JACC 1999; 34(6):1778-1883.
35. Muhlestein JB . Ineffective Endocarditis: How well are we managing our patients? JACC 1999; 33(3):794-795.
36. Muhlestein JB . Do infections cause coronary disease ? The evidence implicating Chlamydia pneumoniae. J Crit Illness 1999; 14(12):652-657,
37. Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, Mixson L, Carlquist JF. Association of lipoprotein lipase gene polymorphisms with coronary artery disease. JACC 1999; 33(4):1013-1020.
38. Tanguay JF, Cantor WJ, Krucoff MW, Muhlestein JB, Barsness GW, Zidar JP, Sketch MH, Tcheng JE, Phillips HR, Stack RS, Kaplan AV, Ohman EM. Local Delivery of Heparin Post-PTCA: A Multicenter Randomized Pilot Study. Cathet and Cardiovasc Intervent 2000; 49:461-467.
39. Anderson JL, Muhlestein JB, Carlquist JF, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger MJ, Horne BD, Lim TH. Chlamydia pneumoniae in coronary artery disease. Circulation 2000; 101(12):el118-el119.
40. Muhlestein JB , Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C. Randomized secondary prevention trial of Azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000; 102:1755-1760.
41. Semaan HB, Gurbel PA, Anderson JL, Muhlestein JB, Carlquist JF, Horne BD, Serebruany VL. Soluble VCAM-1 and E-Selectin, but not ICAM-1, discriminate endothelial injury in patients with documented coronary artery disease. Cardiology 2000; 93:7-10.
42. Anderson JL, Muhlestein JB. The ACADEMIC Study in Perspective (Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia.) J Infectious Dis. 2000 ; 181(suppl 3) :S569-S571.
43. Davidson CJ, Warren KL, Hermiller JB, Harrison JK, Matthei Jr. W, Vliestra RE, Brinker JA, Kereiakes DJ, Muhlestein JB, Lanskey A, Popma JJ, Buchbinder M, Hirshfeld Jr. JW. Randomized Trail on Contrast Medial Utilization in High-Risk PTCA: The COURT Trial. Circulation 2000; 101:2172-2177.
44. Muhlestein JB . Chlamydia pneumoniae-induced therosclerosis in a rabbit model. J Infectious Dis. 2000 ; 181(suppl3) :S505-S507.
45. Rosen H, Muhlestein JB, Bartlett J, Chen S, Chikami G, Corson M, Shah PK, Gurfinkel, E, Handsfield H, Jackson L, Knirsch C, Kronman R, McCutchan JA, Shea S. Collaborative Multidisciplinary Workshop Report: clinical antimicrobial trial for primary and secondary prevention or atherosclerotic cardiovascular disease. J Infectious Dis. 2000 ; 181(suppl 3) :S582-S584.
46. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR. Plasma Homocysteine Predicts Mortality Independently of Tradition Risk Factors and C-Reactive Protein in Patients with Angiographically Defined Coronary Artery Disease. Circulation 2000; 102(11):1227-1232.
47. Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM, Pepine CJ, Kopecky SL, Kleiman NS, Pacchiana CM, Berdan LG, Kitt MM, Simoons ML, Topol EJ, for the PURSUIT Trial Investigators. Management of Patients with Acute Coronary Syndromes in the United Sates by Platelet Glycoprotein IIb/IIIa Inhibition. Circulation 2000; 102:1093-1100.
48. Anderson JL, Habashi J, Carlquist JF, Muhlestein JB, Horne BD, Bair TL, Pearson RR, Hart NI. A Common Variant of the AMPDI Gene Predicts Improved Cardiovascular Survival in Patients with Coronary Artery Disease. JACC 2000; 36(4):1248-1252.
49. Muhlestein JB , Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, Anderson JL. Cytomegalovirus Seropositivity and C-Reactive Protein Have Independent and Combined Predictive Value for Mortality in Patients with Angiographically Demonstrated Coronary Artery Disease. Circulation 2000; 102:1917-1923.
50. Winkelmann BR, Hager J, Kraus WE, Merlini P, Keavney B, Grant PJ, Muhlestein JB, Granger CB. Genetics of coronary heart disease: Current knowledge and research principles. Am Heart J. 2000; 140:S11-S26.
51. Esprit Investigators . Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. The Lancet 2000; 356:2037-44.
52. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL. Statin Therapy, Lipid Levels, C-Reactive Protein and the Survival of Patients with Angiographically Severe Coronary Artery Disease. JACC 2000; 36(6):1774-1780.
53. Gurfinkel E, Bozovich G, Mautner B, Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T. Chlamydia pneumoniae in coronary artery disease. Circulation 2000; 101(12):E118-119.
54. Semaan HB, Gurbel PA, Anderson JL, Muhlestein JB, Carlquist JF, Horne BD, Serebruany VL. The effect of chronic Azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease. J Cardiovasc Pharmacol 2000; 36(4):533-537.
55. Freedman B, Muhlestein JB, Carlquist JF, Madsen TE, Bair TL, Pearson RR, Anderson JL. Cytomegalovirus Seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2001; 103:E20-E21.
56. Zhu J, Nieto J, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective Study of Pathogen Bruden and Risk of Myocardial Infarction or Death. Circulation 2001; 103(1):45-51.
57. Muhlestein JB , Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR, Anderson JL. Usefulness of In-Hospital Prescription of Statin Agents After Angiographic Diagnosis of Coronary Artery Disease in Improving Continued Compliance and Reduced Mortality. JACC 2001; 87(3):257-61.
58. Duffin DC, Muhlestein JB, Allison SB, Horne BD, Fowles RE, Sorensen SG, Revenaugh JR, Bair TL Lappe DL. Femoral Arterial Puncture Management After Percutaneous Coronary Procedures: A Comparison of Clinical Outcomes and Patient Satisfaction Between Manual Compression and Two Different Vascular Closure Devices. J Invasive Cardiol 2001; 13:354-362.
59. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Effron MB, Barden GA, for the ReoPro Readministration Registry Investigators. Abciximab Readministration: Results of the ReoPro Readministration Registry. Circulation 2001; 104:870-875.
60. Horne BD, Muhlestein JB, Strobel GG, Carlquist JF, Bair TL, Anderson JL, Intermountain Heart Collaborative (IHC) Study Group. Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention. Am Heart J 2002; 144(3):491-500.
61. Anderson JL, Horne BD, Carlquist JF, Bair TL, Habashi J, Hart NI, Jones SK, Muhlestein JB, Intermountain Heart Collaborative Study Group. Effect of implementation of folic acid fortification of food on Homocysteine concentrations in subjects with coronary artery disease. Am J Cardiol 2002; 90(5):536-539.
62. Mahdi OSM, Horne BD, Muellen K, Muhlestein JB, Byrne GI. Serum IgG antibodies to Chlamydial heat shock protein 60 but not to human and bacterial homologs is associated with coronary artery disease. Circulation 2002; 106:1659-1663.
63. Allen Maycock CA, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Pearson RR, Anderson JL. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 2002; 40:1777-1785.
64. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL, Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in patients with angina. J Am Coll Cardiol 2002; 39(4):632-637.
65. Zebrack JS, Anderson JL, Allen Maycock CA, Horne BD, Bair TL, Muhlestein JB. Usefulness of High-Sensitivity C-Reactive Protein in Predicting Long-Term Risk of Death or Acute Myocardial Infarction in Patients with Unstable of Stable Angina Pectoris or Acute Myocardial Infarction. Am J Cardiol 2002; 89(2):145-149.
66. Zhu J, Quyyumi AA, Muhlestein JB, Nieto FJ, Horne BD, Zalles-Ganley A, Anderson JL, Epstein SE. Lack of Association of Helicobacter Pylori Infection with Coronary Artery Disease and Frequency of Acute Myocardial Infarction or Death. Am J Cardiol 2002; 89(2):155-158.
67. Bunch TJ, Muhlestein JB, Anderson JL, Horne BD, Bair TL, Jackson JD, Li Q, Lappe DL. Effects of Statins on Six-Month Survival and Clinical Restenosis Frequency After Coronary Stent Deployment. Am J Cardiol 2002; 90(3):299-302.
68. Beddu S, Allen-Brady K, Cheung AK, Horne BD, Bair TL, Muhlestein JB, Anderson JL. Impact of renal failure on the risk of myocardial infarction and death. Kidney International 2002; 62:1776-1783.
69. Jones HU, Muhlestein JB, Jones KW, Bair TL, Lavasani F, Sohrevardi M, Horne BD, Doty D, Lappe DL. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation 2002; 106(12 suppl 1):119-122.
70. Jackson JD, Muhlestein JB, Bunch TJ, Bair TL, Horne BD, Madsen TE, Lappe JM, Anderson JL, Intermountain Heart Collaborative Study Group. Beta-blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization. Am Heart J 2003; 145(5):875-881.
71. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL, Intermountain Heart Collaborative Study Group. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 2003; 107(2):258-263.
72. Muhlestein JB , Anderson JL. Infectious serology and artherosclerosis: how burdensome is the risk? Circulation 2003; 107(2):220-222.
73. Muhlestein JB , Anderson JL, Horne BD, Lavasani F, Allen Maycock CA, Bair TL, Pearson RR, Carlquist JF. Effect of fasting glucose levels on mortality in non-diabetic and diabetic patients with coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003; 146(2):351-358.
74. Carlquist JF, Muhlestein JB, Molhuizen HOF, Horne BD, Hart NI, Bair TL, Anderson JL. The cholesteryl ester transfer protein Taq 1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Hear J 2003: 146:1007-1014.
75. Zebrack JS, Anderson JL, Beddhe S, Horne BD, Bair TL, Cheung A, Muhlestein JB. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol 2003; 42:57-63.
76. Horne BD, Muhlestein JB, Lappe DL, Renlund DG, Bair TL, Bunch TJ, Anderson JL. Less affluent area of residence and lesser-insured status predict an increased risk of death or myocardial infarction after angiographic diagnosis of coronary disease. Ann Epidemiol 2003; ______.
77. O’Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD, for the Investigators in the WIZARD study. Azithromycin for the Secondary Prevention of Coronary Heart Disease Events. The WIZARD Study: A Randomized Controlled Trial. JAMA 2003; 290(11):1459-1466.
78. Anderson JL, Horne BD, Jones HU, Reyna SP, Carlquist JF, Bair TL, Pearson RR, Lappe DL, Muhlestein JB, for the Intermountain Heart Collaborative (IHC) Study Group. Which Features of the Metabolic Syndrome Predict the Prevalence and Clinical Outcomes of Angiographic Coronary Artery Disease? Cardiology 2004; 101:185-193.
79. Anderson JL, Jensen KR, Carlquist JF, Bair TL, Horne BD, Muhlestein JB. Effect of Folic Acid Fortification on Homocysteine-Related Mortality. Am J Med 2004; 116:158-164.
80. Anderson JL, Muhlestein JB. Antibiotic Trials for Coronary Heart Disease. Tex Heart Inst J 2004; 31:33-38.
81. Clarke, Jessica L. Anderson Jl, Carlquist, John F. Roberts Richrd F. Horne Benjamin D, Bair Tami, Kolek Matthew J, Mower, Chrissa P, Crane Ashle M, Roberts William L, Muhlestein J B. Comparison of differing C-Reactive Protein Assay Methods and Their Impact on Cardiovascular Risk Assessment. The American journal of Cardiology vol. 95 January 1, 2005. 0002-9149/05 doi:10.1016/j.amjcard.2004.08.087
82. Kolek Matthew J. Carlquist John F, Muhlestein JB, Whiting Bryant M, Horne Benjamin D, Bair Tami, Anderson JL. Toll-like receptor 4 gene Asp299gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. American Heart Journal volume 148 #6 10.1016/jahj 2004.05.049
83. Anderson JL, Allen Maycock Chole A, Lappe Donald L, Crandall Brian G, Horne Benjamin D, Bair Tami L, Morris Steven R, LI Qunyu, Muhlestein JB. Frequency of Elevation of C-Reactive Protein in Atrial Fibrillation. The American journal of Cardiology Vol. 94 Nov 15,2004 10.1016/j.amjcard.2004.07.108
84. Horne Benjamin D, Camp Nicola J, Muhlestein JB, Cannon-Albright. Evidence for a Heritable Component in Death Resulting From Aortic and Mitral Valve Diseases. Circulation DOI: 10.1161/01.CIR.0000147189.85636.C3
85. Muhlestein JB, Anderson JL, Horne Benjamin D, Carlquist John, Bair Tami, Bunch T. Jared, Pearson Robert R. Early Effects of Statins in Patients With Coronary Artery Disease and High C-Reactive Protein. The American Journal of Cardiology vol. 94 Nov 1,2004 0002-9149/04 doi: 10.1016/j.amjcard.2004.07.074
86. Muhlestein JB, Enoxaprin vs. Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed with and Intgended Early Invasive Strategy.JAMA July 7, 2004 vol. 292,no.1 LOV-RE-16673-1
87. Carlquist John F, Muhlestein JB, Horne Benjamin, Hart Noal I, Lim Tobin, Habashi Jessica, Anderson JG, Anderson JL. Cytomegalovirus stimulated mRNA accumulation and cell surface expression of the Oxidized LDL scavenger receptor, CD36 Elsevier doi: 10-1016/j.atherosclerosis.2004.07.010
88. Lappe Jason M, Muhlestein JB, Lappe Donald L, Badger Rodney, Bair Tami, Brockman Ruth, French Thomas K, Hofmann Linda C. Horne Benjamin, Kralick-Goldberg, Nicponski Nan, Orton Janette A, Pearson Robert, Renlund Dale G, Rimmasch Holly, Roberts Colleen, Anderson JL. Improvements in 1-year Cardiovascular Clinical Outcomes Associated with a Hospital-Based Discharg Medication Program. American College of Physician Ann Intern Med. 2004: 141:446-453
89. B.D. Horne, J.L. Anderson, J.F. Carlquist, J.B. Muhlestein, D. G. Renlund, T.L. Blair, R.R. Pearson and N.J. Camp. Generating Genetic Risk Scores from Intermediate Phenotypes for Use in Association Studies of Clinically Significant Endopoints. Annals of Human Genetics (2005) 69,176-186
90. Matthew J. Kolek, BS. John F. Carlquist, PhD, Surai Thaneemit-Chen, MS Laura C. Lazzeroni, PhD, Bryant M.Whiting, BA, Benjamin D Horne, PhD, MPH, Joseph B. Muhlestein, MD, Philip Lavori, PhD, and Jeffrey L. Anderson, MD. The Role of a Common Adenosine Monophosphate Deaminase (AMPD)-1 Polymorphism in Outcomes of Ischemic And Nonischemic Heart Failure. Journal of Cardiac Failure Vol. 11 NO. 9 2005